FHTX

Foghorn Therapeutics Inc

FHTX, USA

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

https://foghorntx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FHTX
stock
FHTX

Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Lowered by Wall Street Zen MarketBeat

Read more →
FHTX
stock
FHTX

Stifel Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation Nasdaq

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$11.7143

Analyst Picks

Strong Buy

5

Buy

2

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-3.12

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

High

17.68 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-7.73 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-231.33 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 82.15% of the total shares of Foghorn Therapeutics Inc

1.

Flagship Ventures Management, Inc.

(22.4202%)

since

2025/06/30

2.

FMR Inc

(9.7904%)

since

2025/06/30

3.

Bvf Inc

(9.3791%)

since

2025/06/30

4.

Deerfield Management Co

(5.7589%)

since

2025/06/30

5.

Fidelity Growth Compy Commingled Pl S

(4.7643%)

since

2025/07/31

6.

BlackRock Inc

(3.9433%)

since

2025/06/30

7.

Vanguard Group Inc

(3.3339%)

since

2025/06/30

8.

Fidelity Growth Company Fund

(3.2714%)

since

2025/07/31

9.

Euclidean Capital LLC

(2.7839%)

since

2025/06/30

10.

Vanguard Total Stock Mkt Idx Inv

(1.8208%)

since

2025/07/31

11.

Geode Capital Management, LLC

(1.4288%)

since

2025/06/30

12.

Siren, L.L.C.

(1.2749%)

since

2025/06/30

13.

iShares Russell 2000 ETF

(1.2691%)

since

2025/08/31

14.

Point72 Asset Management, L.P.

(1.1829%)

since

2025/06/30

15.

State Street Corp

(0.9617%)

since

2025/06/30

16.

Fidelity Growth Company K6

(0.9455%)

since

2025/07/31

17.

Alphabet Inc

(0.8861%)

since

2025/06/30

18.

Fidelity Series Growth Company

(0.6496%)

since

2025/07/31

19.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6446%)

since

2025/07/31

20.

Fidelity Small Cap Index

(0.585%)

since

2025/06/30

21.

Birchview Capital, LP

(0.55%)

since

2025/06/30

22.

Dafna Capital Management LLC

(0.5315%)

since

2025/06/30

23.

Northern Trust Corp

(0.5072%)

since

2025/06/30

24.

iShares Russell 2000 Growth ETF

(0.3424%)

since

2025/08/31

25.

Jacobs Levy Equity Management, Inc.

(0.3408%)

since

2025/06/30

26.

Fidelity Extended Market Index

(0.3302%)

since

2025/07/31

27.

iShares Biotechnology ETF

(0.3013%)

since

2025/08/31

28.

Vanguard Russell 2000 ETF

(0.2763%)

since

2025/07/31

29.

Sio Capital Management, LLC

(0.2174%)

since

2025/06/30

30.

Wellington Management Company LLP

(0.2093%)

since

2025/06/30

31.

Ameriprise Financial Inc

(0.1985%)

since

2025/06/30

32.

Scs Capital Management LLC

(0.1892%)

since

2025/06/30

33.

Schwab Small Cap Index

(0.1454%)

since

2025/07/31

34.

iShares Russell 2000 Value ETF

(0.143%)

since

2025/08/31

35.

NT R2000 Index Fund - NL

(0.1401%)

since

2025/06/30

36.

State St Russell Sm Cap® Indx SL Cl I

(0.1364%)

since

2025/08/31

37.

iShares Micro-Cap ETF

(0.1311%)

since

2025/08/31

38.

Fidelity Select Biotechnology

(0.1299%)

since

2025/07/31

39.

Extended Equity Market Fund K

(0.1203%)

since

2025/06/30

40.

NT R2000 Index Fund - DC - NL - 3

(0.1117%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.2571

Latest Release

Date

2025-09-30

EPS Actual

-0.25

EPS Estimate

-0.3333

EPS Difference

0.0833

Surprise Percent

24.9925%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Foghorn Therapeutics Inc (FHTX) Stock Details & Analysis - Finnton | Finnton